Foamix Pharmaceuticals Ltd. expects to file FMX101, its topical foam formulation of minocycline, in the US by the end of 2018, for the treatment of moderate to severe acne, and is planning to set up a US sales force of up to 100 individuals, supported by a follow-on share offering on Nasdaq.
If approved, FMX101 is expected to be the only topical minocycline product for acne in the US. The company believes...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)